Primary hyperaldosteronism historical perspective

Revision as of 17:51, 7 July 2017 by Skazmi (talk | contribs)
Jump to navigation Jump to search

Template:Conn syndrome Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

  • Primary hyperaldosteronism (Conn's syndrome) was described for the first time by the Polish internist Michał Lityński.[1]
  • In 1955, Dr Jerome W. Conn the American endocrinologist first described the condition and named it Conn's syndrome. [2]
  • From 1960s to early 1970s, its techniques of diagnosis and treatment were greatly improved by the availability of spironolactone, realization of the renin-angiotensin-aldosterone system, and progress in laboratory tests and adrenal venous sampling.
  • On October 19, 1964, Jerome W. Conn, Edwin L. Cohen and David R. Rovner differentiated between primary and secondary aldosteronism in hypertensive disease.[3]
  • In 1970s, notwithstanding the extensive application of modern imaging modalities, such as CT scanning, adrenal venous sampling and steroid analysis have remained to be the most accurate and reliable localization method.
  • From 1980s, more and more patients with primary aldosteronism were screened out from the hypertensive population by plasma renin activity/plasma aldosterone concentration ratio and cured by surgical interventions; laparoscopic unilateral adrenalectomy has become the generally accepted golden standard of operation.

References

  1. Kucharz EJ (2007). "[Michał Lityński--a forgotten author of the first description on primary hyperaldosteronism]". Pol. Arch. Med. Wewn. (in Polish). 117 (1–2): 57–8. PMID 17642209.
  2. Conn JW, Louis LH. Primary aldosteronism: a new clinical entity. Trans Assoc Am Physicians 1955;68:215-31; discussion, 231-3. PMID 13299331.
  3. Conn JW, Cohen EL, Rovner DR (1985). "Landmark article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By Jerome W. Conn, Edwin L. Cohen and David R. Rovner". JAMA. 253 (4): 558–66. PMID 3881606.

Template:WH Template:WS